MECHANISMS OF CANNABINOID'S ANTIEMETIC ACTIONS

大麻素的止吐作用机制

基本信息

  • 批准号:
    7245005
  • 负责人:
  • 金额:
    $ 17.34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-09-01 至 2008-12-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chemotherapy induces emesis in two phases, immediate and delayed. The immediate phase of vomiting induced by chemo- or radiotherapy can be treated with serotonin 5-HT3 receptor antagonists, however, there is currently no clinically available antiemetic or antiemetic combination therapy that is effective in all patients either for the immediate or the delayed phase. Moreover, although clinical trials indicate that addition of dexamethasone and/or substance P receptor antagonists improve the antiemetic activity of 5-HT3 antagonists in both acute and delayed emesis, these agents are not effective in all patients. (9- Tetrahydrocannabinol ((9-THC) and its synthetic analog, nabilone, are effective antiemetics against chemo- and radiotherapy, and patients who are protected during the immediate phase also respond well during the delayed phase. Recent animal studies have shown that xenobiotic cannabinoids of diverse structure and activity ((9-THC, CP 55, 940 and WIN 55, 212-2) have broadspectrum antiemetic efficacy via cannabinoid CB1 receptors. Indeed, (9-THC and its analogs prevent the acute phase of cisplatin-induced emesis at doses which do not significantly suppress spontaneous motor activity in the least shrew (Cryptotis parva). The goals of this proposal are to define the broadspectrum antiemetic nature of cannabinoids against both the immediate and delayed phases of emesis produced by chemo and radiotherapy as well as revealing by behavioral and biochemical means whether tolerance develop to the antiemetic capacity of xenobiotic cannabinoids. The specific aims are: 1) Further characterization and mechanistic evaluation of broadspectrum antiemetic potential of xenobiotic cannabinoids ((9-THC, WIN 55, 212-2, CP 55, 940) in the least shrew against diverse emetic stimuli such as radiation, substance P and cisplatin-induced delayed emesis; 2) To show whether co-administration of (9-THC can potentiate the antivomiting efficacy of established antiemetics (serotonin 5-HT3-, dopamine D2- and neurokinin NK1-receptor antagonists and dexamethasone) against chemo- and radiotherapy-induced vomiting; 3) Determination of relative development of tolerance to antiemetic and motor suppressive effects of (9-THC by means of behavioral studies, radioligand binding and G-protein assays. The results will have important implications for the therapeutic utility of these "agonist antiemetics".
描述(由申请人提供):化疗诱导呕吐分为两个阶段,即立即和延迟。由化疗或放疗引起的呕吐的即时阶段可以用5-羟色胺5-HT 3受体拮抗剂治疗,然而,目前没有临床上可用的止吐药或止吐药联合治疗对所有患者的即时或延迟阶段有效。此外,尽管临床试验表明,地塞米松和/或物质P受体拮抗剂的添加改善了5-HT 3拮抗剂在急性和迟发性呕吐中的止吐活性,但这些药物并不是对所有患者都有效。(9-四氢大麻酚((9-THC)及其合成类似物,nabilone,是有效的止吐剂对化疗和放疗,和患者谁是保护在立即阶段也反应良好,在延迟阶段。最近的动物研究表明,不同结构和活性的异生物质大麻素(9-THC,CP 55,940和WIN 55,212-2)通过大麻素CB 1受体具有广谱止吐功效。实际上,β-THC及其类似物在不显著抑制小鼩(Cryptotis parva)的自发运动活动的剂量下防止顺铂诱导的呕吐的急性期。该提案的目标是定义大麻素对化疗和放疗产生的呕吐的即时和延迟阶段的广谱止吐性质,以及通过行为和生物化学手段揭示对外源性大麻素止吐能力的耐受性是否发展。具体目标是:1)异生物质大麻素的广谱止吐潜力的进一步表征和机制评估(9-THC,WIN 55,212-2,CP 55,940)对放射线、P物质和顺铂引起的迟发性呕吐的抑制作用; 2)显示是否联合施用β-THC可以增强已建立的止吐药(血清素5-HT 3-,多巴胺D2-和神经激肽NK 1-受体拮抗剂和地塞米松)对抗化疗和放疗诱导的呕吐; 3)通过行为研究确定对β-THC的止吐和运动抑制作用的耐受性的相对发展,放射性配体结合和G蛋白测定。这些结果将对这些“激动剂止吐药”的治疗效用具有重要意义。

项目成果

期刊论文数量(18)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The antiemetic interaction of Delta9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew.
  • DOI:
    10.1016/j.pbb.2008.08.008
  • 发表时间:
    2009-01
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Wang, Yaozhi;Ray, Andrew P.;McClanahan, Bryan A.;Darmani, Nissar A.
  • 通讯作者:
    Darmani, Nissar A.
Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew.
  • DOI:
    10.1016/j.bbr.2008.07.028
  • 发表时间:
    2009-01-03
  • 期刊:
  • 影响因子:
    2.7
  • 作者:
    Ray, Andrew P.;Griggs, Lisa;Darmani, Nissar A.
  • 通讯作者:
    Darmani, Nissar A.
Ablation of least shrew central neurokinin NK1 receptors reduces GR73632-induced vomiting.
最少的shred中央神经蛋白NK1受体的消融减少了GR73632诱导的呕吐。
  • DOI:
    10.1037/a0015733
  • 发表时间:
    2009-06
  • 期刊:
  • 影响因子:
    1.9
  • 作者:
    Ray, Andrew P.;Chebolu, Seetha;Ramirez, Juan;Darmani, Nissar A.
  • 通讯作者:
    Darmani, Nissar A.
Role of Osteopathic Manipulative Treatment in Altering Pain Biomarkers: A Pilot Study
整骨手法治疗在改变疼痛生物标志物中的作用:一项试点研究
Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NISSAR A DARMANI其他文献

NISSAR A DARMANI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NISSAR A DARMANI', 18)}}的其他基金

Substance P tachykininergic NK1 receptor emetic signal transduction pathways
P物质速激能NK1受体催吐信号转导途径
  • 批准号:
    10224743
  • 财政年份:
    2017
  • 资助金额:
    $ 17.34万
  • 项目类别:
Substance P tachykininergic NK1 receptor emetic signal transduction pathways
P物质速激能NK1受体催吐信号转导途径
  • 批准号:
    9380913
  • 财政年份:
    2017
  • 资助金额:
    $ 17.34万
  • 项目类别:
MECHANISMS OF CANNABINOID'S ANTIEMETIC ACTIONS
大麻素的止吐作用机制
  • 批准号:
    7031766
  • 财政年份:
    1999
  • 资助金额:
    $ 17.34万
  • 项目类别:
MECHANISMS OF CANNABINOIDS ANTIEMETIC ACTIONS
大麻素的止吐作用机制
  • 批准号:
    2881760
  • 财政年份:
    1999
  • 资助金额:
    $ 17.34万
  • 项目类别:
MECHANISMS OF CANNABINOIDS ANTIEMETIC ACTIONS
大麻素的止吐作用机制
  • 批准号:
    6174869
  • 财政年份:
    1999
  • 资助金额:
    $ 17.34万
  • 项目类别:
MECHANISMS OF CANNABINOIDS ANTIEMETIC ACTIONS
大麻素的止吐作用机制
  • 批准号:
    6378907
  • 财政年份:
    1999
  • 资助金额:
    $ 17.34万
  • 项目类别:
MECHANISMS OF CANNABINOID'S ANTIEMETIC ACTIONS
大麻素的止吐作用机制
  • 批准号:
    6818748
  • 财政年份:
    1999
  • 资助金额:
    $ 17.34万
  • 项目类别:
MECHANISMS OF CANNABINOID'S ANTIEMETIC ACTIONS
大麻素的止吐作用机制
  • 批准号:
    7122005
  • 财政年份:
    1999
  • 资助金额:
    $ 17.34万
  • 项目类别:
MECHANISMS OF CANNABINOID'S ANTIEMETIC ACTIONS
大麻素的止吐作用机制
  • 批准号:
    7014982
  • 财政年份:
    1999
  • 资助金额:
    $ 17.34万
  • 项目类别:
SEROTONERGIC COMPONENT OF COCAINES ACTIONS
可卡因作用的血清素成分
  • 批准号:
    2120120
  • 财政年份:
    1994
  • 资助金额:
    $ 17.34万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 17.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 17.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 17.34万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 17.34万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 17.34万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 17.34万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 17.34万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 17.34万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 17.34万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 17.34万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了